GLPwatch
Papers (9189)
Page 107 of 154, ranked by citation count.
- Semaglutide for adults living with obesity.
- Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?
- Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity.
- Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?
- Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects.
- Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.
- Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.
- GLP-1 receptor agonists: why is once weekly inferior to once daily?
- Sodium glycocholate liposome encapsulated semaglutide increases oral bioavailability by promoting intestinal absorption.
- Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.
- A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide.
- Glucagon-like peptide-1 analogues exenatide and liraglutide exert inhibitory effect on the early phase of liver regeneration after partial hepatectomy in rats.
- The Effect of Feeding Behavior on Hypothalamus in Obese Type 2 Diabetic Rats with Glucagon-like Peptide-1 Receptor Agonist Intervention.
- GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.
- A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.
- Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine.
- Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.
- Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta-analysis.
- Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
- Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.
- Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.
- Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
- Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics.
- Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
- Exenatide modulates visual cortex responses.
- Effect of Liraglutide on Osteoporosis in a Rat Model of Type 2 Diabetes Mellitus: A Histological, Immunohistochemical, and Biochemical Study.
- Developing a novel exenatide-based incretin mimic (αB-Ex): Expression, purification and structural-functional characterization.
- Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
- Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review.
- Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials.
- Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.
- Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
- Time to unshackle the medical treatment of obesity in the NHS.
- Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
- HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.
- Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
- Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.
- IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin.
- Liraglutide for patients with non-alcoholic steatohepatitis.
- Exenatide stimulates solute-free water clearance by the rat kidney in hyperhydration.
- Glucagon-like peptide-1 analog liraglutide reduces fat deposition in chicken adipocytes.
- Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.
- Incretin mimetics for weight loss forgive nonadherence.
- Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
- Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
- No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.
- Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study
- Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
- Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery.
- Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review.
- Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes.
- Association of IL-17 Inhibitor and SGLT2 Inhibitor with Candida Pyelonephritis.
- Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
- Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages.
- Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
- Liraglutide restores late cardioprotective effects of remote preconditioning in diabetic rats via activation of hydrogen sulfide and nuclear factor erythroid 2-related factor 2 signaling pathway.
- Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.
- Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
- Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis.
- Improved Glycemic Control and Vascular Function and Reduction of Abdominal Fat Accumulation with Liraglutide in a Case of Werner Syndrome with Diabetes Mellitus.